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Abstract
Background: Buruli Ulcer (BU) is a tropical infectious skin disease that is currently treated with 8 weeks of intramuscular
streptomycin and oral rifampicin. As prolonged streptomycin administration can cause both oto- and nephrotoxicity, we
evaluated its long term toxicity by following-up former BU patients that had received either 4 or 8 weeks of streptomycin in
addition to other drugs between 2006 and 2008, in the context of a randomized controlled trial.
Methods: Former patients were retrieved in 2012, and oto- and nephrotoxicity were determined by audiometry and serum
creatinine levels. Data were compared with baseline and week 8 measurements during the drug trial.
Results: Of the total of 151 former patients, 127 (84%) were retrieved. Ototoxicity was present in 29% of adults and 25% of
children. Adults in the 8 week streptomycin group had significantly higher hearing thresholds in all frequencies at long term
follow-up, and these differences were most prominent in the high frequencies. In children, no differences between the two
treatment arms were found. Nephrotoxicity that had been detected in 14% of adults and in 13% of children during
treatment, was present in only 2.4% of patients at long term follow-up.
Conclusions: Prolonged streptomycin administration in the adult study subjects caused significant persistent hearing loss,
especially in the high frequency range. Nephrotoxicity was also present in both adults and children but appeared to be
transient. Streptomycin should be given with caution especially in patients aged 16 or older, and in individuals with
concurrent risks for renal dysfunction or hearing loss.
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Introduction
Buruli ulcer (BU) is a Neglected Tropical Disease caused by
infection with Mycobacterium ulcerans. Necrotic skin lesions charac-
terize the disease, often with typical undermined edges. Treatment
delay may result in disfigurement and functional limitations [1].
Though isolated cases or small outbreaks have been reported in
over 30 countries, the disease is mainly found in endemic areas in
rural West- and Central-Africa, with around 6.000 cases occurring
annually [2–4].
Over the past decade the main mode of treatment has shifted
from surgery to antimicrobial therapy. Several antibiotic regimens
have been proposed and studied, and the current regimen advised
by the World Health Organization consists of 8 weeks of oral
rifampicin and intramuscular streptomycin [5–8]. Although
surgery can be problematic in under-resourced developing
countries due to high costs and low availability, prolonged
streptomycin administration has complications of its own. These
complications are partly related to the parenteral mode of
administration of streptomycin, but also to its intrinsic toxicity,
notably, ototoxicity and nephrotoxicity [9].
Streptomycin induced ototoxicity encompasses damage to both
the cochlea and vestibulum [10], although the effects of vestibular
damage can to some extent be compensated for by the brain, and
so are clinically less prominent [11]. The damage is caused by
reactive oxygen species that are formed by a redox-active complex
of parts of the aminoglycoside and biologically available iron ions
[12]. The most frequently reported manifestations of ototoxicity
are high-frequency sensorineural hearing loss, and vestibular
dysfunction resulting in disequilibrium and loss of the vestibular
ocular-reflex [12]. These side-effects are often transient, but
chronic effects, especially hearing loss, have also been reported.
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The wide range in incidence varies between 5% and 25%,
depending on the specific aminoglycoside drug, patient group
(older age groups are probably more vulnerable), and definition of
ototoxicity including the method of detection [13,14]. The
occurrence of ototoxicity does not appear to be related to the
individual dosages or the frequency of administration per se, but
rather to the cumulative dose, and the age of the patient [15].
Also, there appears to be a modest genetic susceptibility, caused by
a point mutation in mitochondrial DNA [16].
The nephrotoxic effects of streptomycin are most prominent in the
proximal tubule, and transient nephropathy, manifested by a slow
rise in serum creatinine and a decreased glomerular filtration rate, is
observed in 10–20% of therapeutic courses [17]. Unlike aminogly-
coside-induced ototoxicity, long-term kidney damage is uncommon.
It has long been hypothesized that aminoglycoside-induced nephro-
toxicity would lead to increased serum concentrations of the drug,
resulting in ototoxicity, or that some other link between aminogly-
coside induced oto- and nephrotoxicity existed. Several studies have
however been unable to demonstrate such a relationship, and it is
believed that the two are largely independent [15,18,19].
With a total cumulative dose of up to 56 g (15 mg/kg daily with
a 1 g daily maximum, 56 doses), the amount of streptomycin that
is administered to treat BU is higher than in the treatment of
brucellosis, endocarditis, and urinary tract infections, but similar to
the treatment of Mycobacterium avium complex and second line
treatment for tuberculosis. However, no data exist on the long-
term toxicity of the currently recommended regimen of antimi-
crobial therapy in BU. Therefore, we chose to study former BU
patients that participated earlier in a randomized controlled trial
conducted between 2006 and 2008 [20]. In that trial patients were
randomized to receive either 8 or 4 weeks of streptomycin,




The study protocol was approved by the Committee on Human
Research, Publication, and Ethics of the Kwame Nkrumah
University of Science and Technology and the Komfo Anokye
Teaching Hospital, Kumasi (reference number CHRPE/AP/133/
12). Written informed consent was obtained from all participants
aged $12 years, and consent from parents, or legal representatives
of participants aged #18 years.
Sample size and patient recruitment
We retrieved our study subjects among individuals that had
earlier participated in the Burulico trial, conducted between 2006
and 2009 in Ghana, registered with number NCT00321178 at
clinicaltrials.gov. For that trial, patients aged 5 years or older,
clinically diagnosed with early (duration ,6 months), limited
(cross-sectional diameter ,10 cm) M ulcerans infection were
included, and randomized to receive either 8 weeks of streptomy-
cin at 15 mg/kg daily (max 1000 mg daily) and 8 weeks of
rifampicin at 10 mg/kg daily (max 600 mg daily), or 4 weeks of
streptomycin and rifampicin, followed by 4 weeks of rifampicin
and clarithromycin at 7.5 mg/kg daily. Pregnancy, drug intoler-
ance, and renal, hepatic, and acoustic impairment were among the
exclusion criteria, and co-medication with drugs other than the
study drugs occurred in less than 5% of patients, and mainly
consisted of NSAIDs. Patients had a median age of 12 and 30%
were male. Patient characteristics are described in more detail in
Nienhuis et al. [20].
For the present follow-up study, participants were retrieved
between June and November 2012 by visiting their last known
village or through telephone contact if available. If the former
patient was no longer living at the last known village, neighbors,
relatives, and community leaders were asked for additional
information. When a former patient was located, he or she was
informed about the study, given time to consider participation,
and was asked for consent.
Procedures
The equipment and procedure followed for audiometry at
follow-up were identical to those during the drug trial. Audiometry
was performed in a quiet room in one of the two study hospitals of
the BURULICO drug trial with portable Interacoustics AS208
audiometers, with circumaural earphones with noise reducing
Peltor mute cushions. The audiometers were calibrated to ISO64,
both before the drug trial and again before the follow-up.
Biological calibration performed weekly. During a biological
calibration session, a person with known, stable hearing thresholds
was tested. A persistent deviation of 10 dB or more would prompt
acoustic calibration of the audiometer. However, both during the
drug trial and the follow-up study, no acoustic calibration was
necessary. As soundproof rooms were not available at the study
sites, ambient noise (AN) levels were measured with a voltcraft SL-
100 ambient noise meter in dBA filter weighting during each
audiometry session.
The person performing the follow-up audiometry was blinded
to the treatment allocation during the Burulico study, and was
therefore unaware of earlier streptomycin treatment duration.
Both ears were tested, the right ear first. Frequencies were tested in
the following order: 1, 2, 4, 6, 8, 0.5 and 0.25 kHz. Testing started
with presenting a loud tone. Then the intensity was decreased in
steps of 5 dB until the tone was not heard anymore. The last tone
still heard was the level of audibility of the first test run. Then the
intensity was increased with 10 dB before being decreased again in
steps of 5 dB, until the tone was no longer heard (the second test
run). If the results of the two test runs were not identical, the
process was repeated until two identical levels of audibility were
found. This level was considered the hearing threshold. The same
procedure was followed during the drug trial, and so, audiograms
Author Summary
Buruli Ulcer is an infectious skin disease, mainly occurring
in West Africa. Previously, the disease was treated
exclusively by surgery, but in the last decade, effective
treatment with antibiotics has been established. The WHO
recommended regimen consists of 8 weeks of oral
rifampicin combined with intramuscular streptomycin.
However, prolonged use of streptomycin is known to
cause permanent ototoxicity and transient nephrotoxicity.
To study this, we performed audiometry and measured the
serum creatinine in 127 former Buruli ulcer patients who
received either 4 or 8 weeks of streptomycin 4 to 6 years
ago. Ototoxicity was present in 29% of adults and 25% of
children. Adults who received 8 weeks of streptomycin had
significantly worse hearing at long term follow-up, and this
was most prominent in the high frequencies. In children,
no differences between the two groups were found.
Nephrotoxicity that had been detected in 14% of adults
and in 13% of children during treatment, was present in
only 2.4% of patients at long term follow-up. The findings
indicate that caution should be exercised when prescrib-
ing streptomycin to adults for prolonged periods of time.
Treatment regimens for Buruli ulcer that do not contain
streptomycin are desirable and should be investigated.
Long Term Streptomycin Toxicity
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were available for baseline, after 8 weeks of treatment, and at long-
term follow-up. In addition to audiometry, each subject was asked
at follow-up about complaints of hearing loss and dizziness after
completion of treatment.
To detect late nephrotoxic effects of the streptomycin admin-
istration 4–6 years earlier, serum creatinine was measured in a
sample of venous blood (approximately 2 ml) at the same
laboratory, where serum creatinine was measured during the drug
trial, using the same analytic technique. The results were
compared with the measurements at baseline, after 2, 4, 6, and
8 weeks of treatment during the BURULICO study. Patients with
suspected long-term nephrotoxicity were referred to the hospital
for further management.
The total cumulative dose of streptomycin administered was
estimated to be 56 times the daily dose. Individual records of
compliance were not available, but during the drug trial,
streptomycin administration was only performed in participating
hospitals and health centers and was recorded on tally sheets with
compliance approaching 100%.
Data analysis
As aminoglycoside toxicity is reported to occur less frequently in
children [21,22], we analyzed the results separately for those #16
and .16 years of age at the time of receiving streptomycin
treatment during the Burulico trial. For each frequency, the mean
of measurement results of audiometry of both ears was recorded.
As the distribution of hearing thresholds is usually skewed to the
left, differences between the two treatment arms were assessed
with nonparametric Mann-Whitney-U tests. According to the
criteria of the American Speech-Language-Hearing Association
[23], an increased threshold of 20 dB at any one frequency or an
increase of 15 dB at two consecutive frequencies was classified as
hearing loss. Nephrotoxicity was defined as a rise in serum
creatinine at two consecutive assessments during treatment
compared to baseline of $44 mmol/L (0.5 mg/dL) or 50%
[17,24]. As serum creatinine levels increase with age and body
weight, especially muscle mass, it was not possible to make a
meaningful direct comparison between the serum creatinine
concentrations in the present study with those obtained 4–6 years
earlier during the drug trial. Instead, a decrease of the estimated
Glomerular Filtration Rate (eGFR) of .25% in this follow-up
study compared to baseline was defined as long term nephrotox-
icity [25]. In adults, the eGFR was calculated using the Chronic
Kidney Disease Epidemiology Collaboration (CKD-EPI) equation
[26], as this was earlier shown to be superior to other equations in
a Ghanaian population [27]. In children the eGFR was computed
using the revised Schwartz formula [28].
Results
Patient population and retrieval
Of the 151 former participants of the Burulico trial 127
individuals (84%) were retrieved for follow up. Although the trial
had taken place in the Ashanti region of Ghana, many former
patients were not ethnically Ashanti, and had moved away from
the study site, and patients were retrieved in 9 of Ghanas 11
regions, including the three Northern regions more than
700 kilometers and approximately 10 hours by road from the
original study site. 68% of the retrieved former patients were
female, and the median age at follow-up was 18 years. Sixty-eight
percent of our study participants had been 16 or younger at the
time they received treatment during the Burulico trial. Of the 24
former patients not retrieved, 4 were already lost to follow-up
during the Burulico trial, 3 had moved abroad, 2 had deceased,
and the fate of the remaining 15 was unknown. The patients that
were lost to follow-up did not differ significantly from the patients
that were retrieved in terms of baseline and 8 week audiometry
and serum creatinine, age, sex or treatment arm. The median
duration between drug administration and follow-up was 5 years.
Overall, the patients reported to be doing well. 28% reported to
have experienced another disease since their BU was cured, with
most patients reporting malaria, headache, and stomach ache.
One retrieved patient was HIV-positive. Three patients reported
currently taking analgesics, and 2 patients reported currently
taking anti-hypertensives.
Ototoxicity
Twenty-nine percent of adults, and 25% of children were
classified as having hearing loss compared to baseline audiometry
after 8 weeks of treatment, and 31% of adults, and 27% of
children were classified as having hearing loss at long term follow-
up compared to baseline audiometry. Hearing loss after 8 weeks
was significantly associated with hearing loss at long term follow-
up in (p=0.017 by X2), but not in children (p=0.102 by X2). The
average hearing thresholds at long-term follow up for both
treatment arms for adults are shown in Figure 1, and for children
in Figure 2. For adults, no differences between the two treatment
arms existed in any of the frequencies at baseline, and after 8
weeks of treatment, there was a significant difference in hearing
threshold between treatment arms at 6000 Hz (p=0.03) in adults,
while those at 500 (p=0.07), 1000 (p=0.09), and 8000 Hz
(p=0.09) approached significance by Mann-Whitney U test. For
children, there were no significant differences between the
treatment arms at any frequency at baseline or after 8 weeks of
treatment. For both adults and children, univariate associations
between long term ototoxicity and treatment arm, age, sex, total
cumulative dose of streptomycin and complaints of hearing loss
were determined. The results are shown in table 1. The average
(SD) level of ambient noise (AN) was 45.6 (6.5) dB.
From self-report, 10% of adults reported experiencing hearing
loss (5% in the 8 week streptomycin group vs 16% in the 4 week
streptomycin group; p.0.3 by X2) and 12% of children reported
experiencing hearing loss (9% in the 8 week streptomycin group vs
15% in the 4 week streptomycin group; p.0.3 by X2) after
treatment was completed. Ten percent of adults reported
experiencing dizzyness (5% in the 8 week streptomycin group vs
16% in the 4 week streptomycin group; p.0.3 by X2) and 12% of
children reported experiencing dizzyness (9% in the 8 week
streptomycin group vs 15% in the 4 week streptomycin group;
p.0.3 by X2) after treatment was completed. There appeared to
be no association between audiometrically classified and self-
reported hearing loss, as 14% of the patients that were
audiometrically classified as having hearing loss at long term
follow-up also complained of hearing loss vs 9% of patients that
were not audiometrically classified as having hearing loss (p.0.3
by X2).
Nephrotoxicity
During treatment, 14% of adults, and 13% of children were
classified as having nephrotoxicity. At long term follow-up 1 adult
(2.4%) and 2 children (2.4%) were classified as having long-term
nephrotoxicity. All 3 of these patients had received streptomycin
for 8 weeks (p,0.1 by X2), but only 1 was also classified as having
nephrotoxicity during treatment. The average serum creatinine
concentrations for both treatment arms for adults are shown in
Figure 3, and for children in Figure 4. For both adults and
children, univariate associations between nephrotoxicity and
Long Term Streptomycin Toxicity
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treatment arm, age, weight, sex, and total cumulative dose of
streptomycin were determined. The results are shown in table 2.
Discussion
In this study we followed-up individuals that were randomly
assigned to either 4 or 8 weeks of streptomycin injections 4 to 6
years earlier, and that had similar results in audiometry at
baseline. This provided a unique model to compare long-term
toxicity incurred by doubling the cumulative dosage of strepto-
mycin. In adults, we found an important and clinically relevant
increase in hearing loss in the high frequencies in individuals that
had received 8 weeks of streptomycin, in comparison to those that
had received only 4 weeks of this aminoglycoside. In children, no
differences between the two treatment arms were detectable.
Although macrolides, especially, azithromycin have also been
connected to hearing loss [29], the ototoxicity associated with
prolonged streptomycin use was significantly more pronounced
than in individuals that had received clarithromycin instead.
Figure 1. Hearing thresholds of adults at long term follow-up. Mean hearing thresholds of adults (16 or older at the time of treatment) in dB
averaged over both ears. The shaded area represents the area used in understanding human speech (Pascoe, 1980) [37]. SR8= participants in the 8
week Streptomycin/Rifampicin group. SR4/CR4=participants in the 4 week Streptomycin/Rifampicin plus 4 week Clarithromycin/Rifampicin group.
The Differences between the two groups were tested with the Mann-Whitney U test, 1-tailed. * = p,0.05, ** = p,0.001.
doi:10.1371/journal.pntd.0002739.g001
Figure 2. Hearing thresholds of children at long term follow-up. Mean hearing thresholds of children (under 16 at the time of treatment) in
dB averaged over both ears. The shaded area represents the area used in understanding human speech (Pascoe, 1980) [37]. SR8= participants in the 8
week Streptomycin/Rifampicin group. SR4/CR4=participants in the 4 week Streptomycin/Rifampicin plus 4 week Clarithromycin/Rifampicin group.
The Differences between the two groups were tested with the Mann-Whitney U test, all differences were ns.
doi:10.1371/journal.pntd.0002739.g002
Long Term Streptomycin Toxicity
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The ototoxic effects of prolonged duration of streptomycin
therapy appeared to differ between adults and children. To our
knowledge, no studies have evaluated the ototoxicity of an
aminoglycoside in a study population consisting of both children
and adults suffering from the same illness, exposed to the same
treatment schedule. Low levels of ototoxicity in children have been
reported before [21,22], but the exact mechanisms for this
interaction with age are not well understood [21].
The incidence of hearing loss in our study was slightly higher
than in earlier reports, which may be due to the fact that we used
the formal ASHA criteria that are designed to detect early
changes, so as to avoid more severe damage with ongoing
aminoglycoside administration.
In children, there was only a weak relationship between hearing
loss detected by audiometry and complaints of hearing loss by the
patient, and in adults there was no relationship at all. Audiometric
and subjective ototoxicity often correlate poorly [15,30,31],
because audiometric toxicity is usually – as in our study – present
in the high frequencies. High frequency hearing loss does not
affect primary speech hearing, but rather affects the ability to
follow group conversations, and causes people to hear the wrong
words without noticing it [32]. This may explain why many
clinicians are not very concerned about ototoxicity in the
treatment of BU, as their patients usually do not report hearing
loss spontaneously.
In our study, nephrotoxicity was present in both children and
adults, occurred more often in the 8 week streptomycin group and
appeared to be related to the total cumulative dose of streptomy-
cin. However, long term nephrotoxicity was only detected in 3
study subjects. The occurrence of both transient and long-term
streptomycin nephrotoxicity in our study might be a low estimate
for the population at risk in general, as BU is a local infection,
usually without systemic involvement, and most patients were
young and did not have any significant comorbidities, medical
history or co-medication, contrary to other patient categories that
are administered aminoglycosides, e.g. ICU patients or those with
cystic fibrosis. In addition, streptomycin was administered once
daily, which is known to reduce the incidence of nephrotoxicity
[33].
Our study had several limitations. First, after an intensive
search, we only retrieved 127 (84%) of the population that we
Table 1. Univariate associations with long term ototoxicity.
Adults (N=41) Ototoxicity
Yes No P value
Treatment arm
8 weeks streptomycin 40% 60%
4 weeks streptomycin 23% 77% .114
Age during treatment (SD) 32(17) 27(11) .150
Sex
Male 57% 43%
Female 26% 74% .101
Total grams of streptomycin (SD) 40(15) 34(13) .090
Complaints of hearing loss
Yes 25% 75%
No 32% 68% .393
Children(N=86) Ototoxicity
Yes No P value
Treatment arm
8 weeks streptomycin 26% 74%
4 weeks streptomycin 28% 72% .414
Age during treatment (SD) 10(3) 9(3) .274
Sex
Male 24% 76%
Female 29% 71% .505
Total grams of streptomycin (SD) 23(12) 21(9) .220
Complaints of hearing loss
Yes 40% 60%
No 25% 75% .164
All P values are 1-tailed except for sex.
doi:10.1371/journal.pntd.0002739.t001
Figure 3. Serum creatinine levels in adults at long term follow-
up. Mean (SD) serum creatinine concentrations of adults (16 or older at
the time of treatment), measured at baseline, after 8 weeks of treatment
and at long term follow-up. SR8 = participants in the 8 week
Streptomycin/Rifampicin group. SR4/CR4=participants in the 4 week
Streptomycin/Rifampicin plus 4 week Clarithromycin/Rifampicin group.
The differences between the two groups at baseline were tested with
the students t-test. The differences between the two groups after 8
weeks of treatment and at long-term follow up were tested with an
ANCOVA, controlling for serum creatinine concentration at baseline and
age. * = p,0.05, others ns (N=41).
doi:10.1371/journal.pntd.0002739.g003
Figure 4. Serum creatinine levels in children at long term
follow-up. Mean (SD) serum creatinine concentrations of children
(under 16 at the time of treatment), measured at baseline, after 8 weeks
of treatment and at long term follow-up. SR8= participants in the 8
week Streptomycin/Rifampicin group. SR4/CR4=participants in the 4
week Streptomycin/Rifampicin plus 4 week Clarithromycin/Rifampicin
group. The differences between the two groups were tested with the
students t-test. All differences ns (N= 84).
doi:10.1371/journal.pntd.0002739.g004
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intended to study. Of the 24 subjects that were lost to follow-up,
we could not detect features that might have introduced bias, but
we cannot completely rule out that some bias was introduced.
Next, although the group that was earlier exposed to 4 weeks of
streptomycin had (near) normal audiograms, we did not attempt to
enroll a matched control group that had not had streptomycin
injections. Also, variability between measurements is likely to be
higher than desirable, due to high levels of AN, although average
levels of AN were only slightly higher compared to accepted
bedside testing levels in the USA [34,35]. This implies that the
absolute numbers of hearing loss should be interpreted with
caution, but as AN levels were similar for all measurements, it is
not likely to have influenced the differences found between the two
treatment arms.
The strength of our findings is that we could detect a difference
between groups that appeared well matched. With known baseline
characteristics, with a well-documented increased exposure to
streptomycin, we conclude that prolonged streptomycin adminis-
tration in the adult study subjects caused significant hearing loss,
especially in the high frequency range. In addition, we obtained
ototoxicity data from a patient sample that included both adults
and children suffering from the same illness and receiving the same
treatment, with differential effects in terms of toxicity.
Our study results support ongoing attempts to try replacing
injected streptomycin by an alternative, e.g. clarithromycin. Cur-
rently a trial to compare standard care (streptomycin plus rifampicin)
with oral treatment consisting of clarithromycin in extended release
formulation combined with rifampicin is ongoing [36].
We conclude that streptomycin with cumulative dosages,
especially in patients aged 16 or older should be given with
caution, especially in individuals with concurrent risks for renal
dysfunction or hearing loss.
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